(Q38364635)

2 September 2017

1 reference

title

Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations (English)

1 reference

2 September 2017

1 reference

Daan Joost De Maeseneer

1

1 reference

2 September 2017

Charles Van Praet

2

1 reference

2 September 2017

Nicolaas Lumen

3

1 reference

2 September 2017

Sylvie Rottey

4

1 reference

2 September 2017

publication date

20 February 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

33

1 reference

2 September 2017

issue

7

1 reference

2 September 2017

page(s)

310-321

1 reference

Cancer treatment and survivorship statistics, 2014

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

European cancer mortality predictions for the year 2014.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Population screening for prostate cancer: an overview of available studies and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Androgen insensitivity syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

The CAG repeat within the androgen receptor gene and its relationship to prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Molecular biology of the androgen receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Molecular alterations during progression of prostate cancer to androgen independence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Androgen deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Angiogenesis in prostate cancer: onset, progression and imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Prostate cancer: androgen deprivation causes EMT in the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Radionuclide therapy for osseous metastases in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Human steroid biosynthesis for the oncologist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Abiraterone in metastatic prostate cancer without previous chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Increased survival with enzalutamide in prostate cancer after chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Enzalutamide in metastatic prostate cancer before chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Abiraterone and increased survival in metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

ARN-509: a novel antiandrogen for prostate cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Poor survival in prostate cancer patients with primary refractoriness to docetaxel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.01.008

10.1016/J.UROLONC.2015.01.008

7 January 2021

Identifiers

DOI

1 reference

2 September 2017

1 reference